EMA warns of possible medication errors when developing new forms and indications
This article was originally published in Scrip
Executive Summary
In yet another move spurred by the new EU pharmacovigilance legislation, companies proposing to market products similar to ones already on the market are being asked to take extra steps to prevent potential medication errors, particularly with substances that have a narrow therapeutic index.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.